Abstract
An accurate identification of schizophrenia spectrum disorder (SSD) at early stage could potentially allow for treating SSD with appropriate intervention to potentially prevent future deterioration. Despite mounting studies found neuroimaging combined with machine learning can identify chronic medicated SSD, whether or not the classification model identified the trait biomarker of SSD that can be used to identify early stage SSD is largely unknown. The present study aimed to investigate whether or not the classification model trained using chronic medicated SSD identified the trait biomarker of SSD that whether or not the model can be generalized to early stage SSD, by using functional connectivity (FC) combined with support vector machine (SVM) using a large sample from 4 independent sites (n = 1077). We found that the classification model trained using chronic medicated SSD from three sites(dataset 2, 3 and 4) classified SSD from HCs in another site (dataset 1) with 69% accuracy (P = 2.86e-13). Subgroup analysis indicated that this model can identify chronic medicated SSD in dataset 1 with 71% sensitivity (P = 4.63e-05), but cannot be generalized to first episode unmedicated SSD (sensitivity = 48%, P = 0.68) and first episode medicated SSD (sensitivity = 59%, P = 0.10). Univariable analysis showed that medication usage had significant effect on FC, but disease duration had no significant effect on FC. These findings suggest that the classification model trained using chronic medicated SSD may mainly identified the pattern of chronic medication usage state, rather than the trait biomarker of SSD. Therefore, we should reconsider the current machine learning studies in chronic medicated SSD more cautiously in term of the clinical application.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by National Key R&D Program of China (Grant 2018YFC1311600 and 2016YFC1306900 to Yanqing Tang), Liaoning Revitalization Talents Program (Grant XLYC1808036 to Yanqing Tang), Science and Technology Plan Program of Liaoning Province (2015225018 to Yanqing Tang), National Science Fund for Distinguished Young Scholars (81725005 to Fei Wang), Liaoning Education Foundation (Pandeng Scholar to Fei Wang), Innovation Team Support Plan of Higher Education of Liaoning Province (LT2017007 to Fei Wang), Major Special Construction Plan of China Medical University (3110117059 and 3110118055 to Fei Wang).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics Committee of the First Affiliated Hospital of China Medical University
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data used in this work can be requested from the corresponding author
